Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: A meta-analysis

World Journal of Gastroenterology

Volumn 20, Issue 20, 2014, Pages 6336-6344

  Li, Jia ^a,b   Gao, Jian Zhi ^a,c   Du, Jing Li ^a   Wei, Li Xin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NANKAI UNIVERSITY   (China)

^c XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Clinicopathological parameter; Glypican 3; Hepatocellular carcinoma; Meta analysis; Prognosis

Indexed keywords

GLYPICAN 3; GLYPICAN;

ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; DATA EXTRACTION; DISEASE FREE SURVIVAL; GENE OVEREXPRESSION; HAZARD RATIO; HUMAN; INFORMATION PROCESSING; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; META ANALYSIS; METASTASIS; OVERALL SURVIVAL; PATHOLOGY; PUBLISHING; QUANTITATIVE ANALYSIS; TUMOR DIFFERENTIATION; TUMOR INVASION; CELL DIFFERENTIATION; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MORTALITY; PROGNOSIS; RISK; TREATMENT OUTCOME; TUMOR RECURRENCE;

CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYPICANS; HUMANS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; TREATMENT OUTCOME;

EID: 84901501647     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i20.6336     Document Type: Article

References (39)

1. Shiraha H, Yamamoto K, Namba M. Human hepatocyte carcinogenesis (review). Int J Oncol 2013; 42: 1133-1138 [PMID: 23426905 DOI: 10.3892/ijo.2013.1829]
2. Zhou Y, Sui C, Li B, Yin Z, Tan Y, Yang J, Liu Z. Repeat hepatectomy for recurrent hepatocellular carcinoma: a local experience and a systematic review. World J Surg Oncol 2010; 8: 55 [PMID: 20591196 DOI: 10.1186/1477-7819-8-55]
3. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005; 23: 2892-2899 [PMID: 15860847 DOI: 10.1200/JCO.2005.03.196]
4. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest 2001; 108: 497-501 [PMID: 11518720 DOI: 10.1172/JCI13712]
5. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89-97 [PMID: 12851874]
6. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, Tokita S, Iwanari H, Ito Y, Nakano K, Nezu J, Tsunoda H, Yoshino T, Ohizumi I, Tsuchiya M, Ohnishi S, Makuuchi M, Hamakubo T, Kodama T, Aburatani H. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004; 64: 2418-2423 [PMID: 15059894]
7. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306: 16-25 [PMID: 12788060]
8. Wang XY, Degos F, Dubois S, Tessiore S, Allegretta M, Guttmann RD, Jothy S, Belghiti J, Bedossa P, Paradis V. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006; 37: 1435-1441 [PMID: 16949914 DOI: 10.1016/j.humpath.2006.05.016]
9. Kandil DH, Cooper K. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol 2009; 16: 125-129 [PMID: 19550373 DOI: 10.1097/ PAP.0b013e3181992455]
10. Libbrecht L, Severi T, Cassiman D, Vander Borght S, Pirenne J, Nevens F, Verslype C, van Pelt J, Roskams T. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006; 30: 1405-1411 [PMID: 17063081 DOI: 10.1097/01.pas.0000213323.97294.9a]
11. Liu H, Li P, Zhai Y, Qu CF, Zhang LJ, Tan YF, Li N, Ding HG. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 2010; 16: 4410-4415 [PMID: 20845507]
12. Ozkan H, Erdal H, Koçak E, Tutkak H, Karaeren Z, Yakut M, Köklü S. Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. J Clin Lab Anal 2011; 25: 350-353 [PMID: 21919070 DOI: 10.1002/jcla.20484]
13. Tangkijvanich P, Chanmee T, Komtong S, Mahachai V, Wisedopas N, Pothacharoen P, Kongtawelert P. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol 2010; 25: 129-137 [PMID: 19793164 DOI: 10.1111/j.1440-1746.2009.05988.x]
14. Xu C, Yan Z, Zhou L, Wang Y. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2013; 139: 1417-1424 [PMID: 23743582 DOI: 10.1007/s00432-013-1458-5]
15. Li L, Jin R, Zhang X, Lv F, Liu L, Liu D, Liu K, Li N, Chen D. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma. Hepatology 2012; 56: 1380-1390 [PMID: 22706665 DOI: 10.1002/hep.25891]
16. Gao W, Ho M. The role of glypican-3 in regulating Wnt in hepatocellular carcinomas. Cancer Rep 2011; 1: 14-19 [PMID: 22563565]
17. Cheng W, Tseng CJ, Lin TT, Cheng I, Pan HW, Hsu HC, Lee YM. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis 2008; 29: 1319-1326 [PMID: 18413366 DOI: 10.1093/carcin/bgn091]
18. Liu S, Li Y, Chen W, Zheng P, Liu T, He W, Zhang J, Zeng X. Silencing glypican-3 expression induces apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 2012; 419: 656-661 [PMID: 22382024 DOI: 10.1016/ j.bbrc.2012.02.069]
19. Lin Q, Xiong LW, Pan XF, Gen JF, Bao GL, Sha HF, Feng JX, Ji CY, Chen M. Expression of GPC3 protein and its significance in lung squamous cell carcinoma. Med Oncol 2012; 29: 663-669 [PMID: 21556932 DOI: 10.1007/s12032-011-9973-1]
20. Mounajjed T, Zhang L, Wu TT. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms. Hum Pathol 2013; 44: 542-550 [PMID: 23079207 DOI: 10.1016/ j.humpath.2012.06.016]
21. Komori H, Beppu T, Baba H, Nakatsura T, Nishimura Y. Assessment of serum GPC3 as a tumor marker for hepatocellular carcinoma and malignant melanoma. Nihon Rinsho 2010; 68 Suppl 7: 833-836 [PMID: 20960882]
22. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-605 [PMID: 20652370 DOI: 10.1007/s10654-010-9491-z]
23. Wells GA, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011. Available from: URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
24. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834 [PMID: 9921604]
25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558 [PMID: 12111919 DOI: 10.1002/sim.1186]
26. Ning S, Bin C, Na H, Peng S, Yi D, Xiang-hua Y, Fang-yin Z, Da-yong Z, Rong-cheng L. Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients. Mol Biol Rep 2012; 39: 351-357 [PMID: 21655958 DOI: 10.1007/s11033-011-0745-y]
27. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009; 100: 1403-1407 [PMID: 19496787 DOI: 10.1111/ j.1349-7006.2009.01206.x]
28. Wang YL, Zhu ZJ, Teng DH, Yao Z, Gao W, Shen ZY. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. World J Gastroenterol 2012; 18: 2408-2414 [PMID: 22654434 DOI: 10.3748/wjg.v18.i19.2408]
29. Yorita K, Takahashi N, Takai H, Kato A, Suzuki M, Ishiguro T, Ohtomo T, Nagaike K, Kondo K, Chijiiwa K, Kataoka H. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. Liver Int 2011; 31: 120-131 [PMID: 20964802 DOI: 10.1111/ j.1478-3231.2010.02359.x]
30. Yu MC, Lee YS, Lin SE, Wu HY, Chen TC, Lee WC, Chen MF, Tsai CN. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol 2012; 19 Suppl 3: S455-S463 [PMID: 21822558 DOI: 10.1245/ s10434-011-1946-2]
31. E Y, He N, Wang Y, Fan H. Percutaneous transluminal angioplasty (PTA) alone versus PTA with balloon-expandable stent placement for short-segment femoropopliteal artery disease: a metaanalysis of randomized trials. J Vasc Interv Radiol 2008; 19: 499-503 [PMID: 18375292 DOI: 10.1016/ j.jvir.2007.12.446]
32. Honsová E, Lodererová A, Franková S, Oliverius M, Trunecka P. Glypican-3 immunostaining significantly improves histological diagnosis of hepatocellular carcinoma. Cas Lek Cesk 2011; 150: 37-40 [PMID: 21400962]
33. Zhang L, Liu H, Sun L, Li N, Ding H, Zheng J. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study. Acta Histochem 2012; 114: 547-552 [PMID: 22119409 DOI: 10.1016/ j.acthis.2011.10.003]
34. Sun CK, Chua MS, He J, So SK. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. Neoplasia 2011; 13: 735-747 [PMID: 21847365]
35. Ruan J, Liu F, Chen X, Zhao P, Su N, Xie G, Chen J, Zheng D, Luo R. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line. Int J Mol Med 2011; 28: 497-503 [PMID: 21617840 DOI: 10.3892/ ijmm.2011.704]
36. Li C, Li Z, Zhu M, Zhao T, Chen L, Ji W, Chen H, Su C. Clinicopathological and prognostic significance of survivin over-expression in patients with esophageal squamous cell carcinoma: a meta-analysis. PLoS One 2012; 7: e44764 [PMID: 23028610 DOI: 10.1371/journal.pone.0044764]
37. Zhang LQ, Wang J, Jiang F, Xu L, Liu FY, Yin R. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS One 2012; 7: e34100 [PMID: 22457815 DOI: 10.1371/journal. pone.0034100]
38. Allegretta M, Filmus J. Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma. Anticancer Agents Med Chem 2011; 11: 543-548 [PMID: 21554204]
39. Ho M, Kim H. Glypican-3: a new target for cancer immune-therapy. Eur J Cancer 2011; 47: 333-338 [PMID: 21112773 DOI: 10.1016/j.ejca.2010.10.024]